Impella

Type: Product
Name: Impella
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

ABIOMED : Controllers Engineering Service Sought by Veterans Affairs

By Targeted News ServiceWASHINGTON , Sept. 27 -- The U.S. Veterans Affairs Department's Long Beach Healthcare System , Long Beach, California , has issued a pre-solicitation notice (VA26214Q1575) for engineering service for two Abiomed Impella automated ... [Published 4 Traders - Sep 30 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Trade Press Release: CAE Healthcare delivers simulation-based training solution to Abiomed for its Impella heart pump

By a News Reporter-Staff News Editor at Cardiovascular Week -- CAE Healthcare announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2014, the world's largest educational meeting specializing in interventional cardiovascular medicine, that it ... [Published 4 Traders - Sep 24 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

US Federal Business Opportunity: Department of Veterans Affairs: J--Service Contract for Government Owned ABIOMED Imepella Controllers

Agency: Department of Veterans AffairsOffice: Long Beach VANLO Location: Department of Veterans AffairsDate you need to respond by: 29-September-2015Solicitation Number: VA26214Q1575 Naics code: 334510 Computer and Electronic Product ManufacturingDe ... [Published ITbriefing - Sep 24 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Abiomed appoints director of investor relations

Abiomed Inc., a provider of heart support technologies, has appointed Ingrid Goldberg as director of investor relations. "We are extremely pleased to have Ingrid on board during a pivotal time of growth and opportunity for the Company," said Michael R. ... [Published Individual.com - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

VADs Gaining Popularity, But Artificial Hearts Remain the Ideal, Says GlobalData Analyst

— Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said:“Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly in size, design and power usage, but many problems related ... [Published Diagnostic & Invasive Cardiology - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Update: Abiomed Announced Clinical Trial Results For Impella RP

Summary Abiomed announced RECOVER RIGHT clinical trial results for Impella RP earlier this week. In my original article I mentioned that Abiomed started enrolling patients for the RECOVER RIGHT clinical trial. The result remained promising for the ... [Published Seeking Alpha - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

CAE Healthcare announces supply of simulation-based solution to Abiomed

CAE Healthcare, a medical simulation company, has announced the supply of a simulation-based solution to Abiomed, a manufacturer of medical implant devices, for its Impella heart pump education programs. Using the CAE VIMEDIX platform as a springboard, ... [Published Individual.com - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Abiomed Inc. Announces Clinical Trial Results For RECOVER RIGHT; Oncolytics Reports from US Randomized Phase 2 Pancreatic Cancer Study

Below is a look at some of the headlines for companies that made news in the healthcare sector on September 16, 2014.Abiomed Inc. (Nasdaq: ABMD) , a leading provider of breakthrough heart support technologies, today announced clinical trial results from ... [Published BioMedReports - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

CAE Healthcare Provides Abiomed Solution for Impella Heart Pump Program

CAE Healthcare reported at the Transcatheter Cardiovascular Therapeutics 2014 that it is delivering a simulation-based solution to Abiomed for its Impella heart pump education programs. According to a release from the company, using the CAE Vimedix platform ... [Published Individual.com - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 2 reports

Clinical Trial Results For Impella RP Right Ventricular Heart Failure Trial "Recover Right" Released At TCT 2014

Abiomed Inc. (Nasdaq: ABMD[1]), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Percutaneous) System. The ... [Published DailyMe.Com - Sep 17 2014]
First reported Sep 13 2014 - Updated Sep 13 2014 - 3 reports

CAE Healthcare Delivers Simulation-based Training Solution To Abiomed

CAE Healthcare, a unit of Canadian aviation-training and simulation products provider CAE, Inc. (CAE: Quote,CAE.TO: Quote) Saturday said it is delivering a simulation-based solution to Abiomed, Inc. (ABMD: Quote), a provider of breakthrough heart support ... [Published RTTNews.com - Sep 13 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Data From RECOVER RIGHT Impella RP Trial to be Announced at TCT 2014

Abiomed Completes FDA HDE Submission for Impella RPDANVERS, Mass., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced that data from RECOVER RIGHT, an Investigational ... [Published Scottrade - Sep 10 2014]

Quotes

...technologies to supplement our educational programs," said Michael R Minogue , Chairman President and ChiefChief Executive Officer, of Abiomed . "Our partnership with CAE demonstrates our responsibility to providing high quality training tools for our customers."
...thrilled to be joining the Abiomed team and have already witnessed several live cases and the impact of Impella in the cath lab," said Ms Goldberg. "The Company's compelling and innovative product portfolio, alongside the mission of providing breakthrough, minimally invasive, heart support technologies, have me eager to contribute to Abiomed becoming the new standard of care for patients requiring hemodynamic support."
...Michael R Minogue, Abiomed's Chairman, President and CEO, said, "The Impella RP is the first percutaneous, single vascular access pump designed for right heart support. The pump is designed to be used concurrently with other left ventricle pumps in the Impella platform, which in the future may offer physicians the option of percutaneous biventricular support for acute patients."
...Alan Tuchman, Senior Vice President, Medical and Clinical Affairs & Chief Medical Officer of Oncolytics. "These findings support previous evidence of REOLYSIN® being active in cancer cells with an activated RAS pathway and warrants confirmation of KRAS status as a potential predictive biomarker in future studies."

More Content

All (32) | News (23) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
ABIOMED : Controllers Engineering Service Sough... [Published 4 Traders - Sep 30 2014]
Trade Press Release: CAE Healthcare delivers si... [Published 4 Traders - Sep 24 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Sep 24 2014]
Abiomed appoints director of investor relations [Published Individual.com - Sep 22 2014]
VADs Gaining Popularity, But Artificial Hearts ... [Published Diagnostic & Invasive Cardiology - Sep 22 2014]
Update: Abiomed Announced Clinical Trial Result... [Published Seeking Alpha - Sep 19 2014]
CAE Healthcare announces supply of simulation-b... [Published Individual.com - Sep 18 2014]
Abiomed Appoints Ingrid Goldberg as Director of... [Published Fat Pitch Financials - Sep 18 2014]
CAE Healthcare Provides Abiomed Solution for Im... [Published Individual.com - Sep 17 2014]
Clinical Trial Results For Impella RP Right Ven... [Published DailyMe.Com - Sep 17 2014]
Abiomed Inc. Announces Clinical Trial Results F... [Published BioMedReports - Sep 17 2014]
Clinical Trial Results for Impella RP Right Ven... [Published GlobeNewswire: Music News - Sep 16 2014]
Clinical Trial Results for Impella RP Right Ven... [Published SPi World News - Sep 16 2014]
TSX Ends Lower On Global Growth Worries -- Cana... [Published RTTNews.com - Sep 15 2014]
Canadian Stocks Drift Lower On Global Economic ... [Published RTTNews.com - Sep 15 2014]
CAE Healthcare Delivers Simulation-based Traini... [Published RTTNews.com - Sep 13 2014]
Trade Press Release: CAE Healthcare delivers si... [Published MarketWired - Sep 13 2014]
Trade Press Release: CAE Healthcare delivers si... [Published Marketwire - Breaking News Releases - Sep 13 2014]
Ventricular Assist Devices Gaining Popularity, ... [Published Medical Design Technology - Sep 11 2014]
Enanta Reports Initiation of ABT-493 Phase 2B; ... [Published BioMedReports - Sep 11 2014]
Data From RECOVER RIGHT Impella RP Trial to be ... [Published GlobeNewswire: Acquisitions News - Sep 10 2014]
Data From RECOVER RIGHT Impella RP Trial to be ... [Published Scottrade - Sep 10 2014]
ABIOMED : Patent Issued for Loading Guide Lumen [Published 4 Traders - Sep 04 2014]
Abiomed, Inc. (ABMD) - Product Pipeline Analysi... [Published MarketResearch.com - Aug 28 2014]
ABIOMED Makes a Move: Up 1.8%... [Published Financial News Network online - Aug 26 2014]
Forbion Capital to sell Santaris Pharma to Roch... [Published PE Hub Blog - Aug 05 2014]
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Trade Press Release: CAE Healthcare delivers si... [Published Marketwire - Breaking News Releases - Sep 13 2014]
CAE VIMEDIX Impella simulator allows physicians to practice placement of device in the left ventricle using fluoroscopic and ultrasound guidance ...
Forbion Capital to sell Santaris Pharma to Roch... [Published PE Hub Blog - Aug 05 2014]
Forbion Capital Partners has sold biopharmaceutical company Santaris Pharma A/S for $450 million to Roche . The deal is structured with an upfront cash payment of $250 million and additional contingent payments of up to $200 million based on achievement ...
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners ‘ portfolio company. PRESS RELEASE Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1

Press Releases

sort by: Date | Relevance
Clinical Trial Results for Impella RP Right Ven... [Published GlobeNewswire: Music News - Sep 16 2014]
Data From RECOVER RIGHT Impella RP Trial to be ... [Published GlobeNewswire: Acquisitions News - Sep 10 2014]
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.